Tag: R

Retrophin to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series

SAN DIEGO, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih, M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday, September 28, 2016 at 11:05 a.m. ET. A live webcast of the…

InterDigital Joins Avanci IoT Licensing Platform

WILMINGTON, Del., Sept. 14, 2016 (GLOBE NEWSWIRE) -- InterDigital, Inc. (NASDAQ:IDCC), a mobile technology research and development company, today announced that it has joined Avanci, the industry’s first marketplace for the licensing of cellular standards-essential technology for the Internet of Things (IoT). The licensing platform brings together some of InterDigital’s peers in standards-essential technology leadership,…

LifeSci Advisors Announces Opening of Office in Tel-Aviv, Israel

NEW YORK, Sept. 14, 2016 (GLOBE NEWSWIRE) -- LifeSci Advisors, a New York-based, life sciences focused investor relations consultancy, is pleased to announce today the opening of an office in Tel-Aviv, Israel.  The establishment of an Israeli office, together with the recent expansion of its European team, reflects LifeSci Advisors’ increasing international focus. Israel was selected…

Synaptics Enhances Broad Automotive Portfolio with Three New Touch Controllers

SAN JOSE, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Synaptics Incorporated (NASDAQ:SYNA), the leading developer of human interface solutions, today announced three new feature-rich touch controller solutions designed specifically for the quality and reliability requirements and lifetime needs of the automotive market. The new Synaptics ClearPad® automotive solutions include S7880, S7881, and S7882 touchscreen controllers…

INC Research and CISCRP Announce Finalists for “Inspiring Hope” Ideathon

RALEIGH, N.C., Sept. 14, 2016 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, together with the Center for Information and Study on Clinical Research Participation (CISCRP), a non-profit organization dedicated to engaging the public and patients as partners in the clinical research process, today announced…

Greystone Provides $45 Million Bridge Loan for Acquisition of Tampa Multifamily Portfolio

NEW YORK, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Greystone, a real estate lending, investment and advisory company, today announced it has provided a $45,000,000 bridge loan for the acquisition of Tampa Woods Apartments (formerly known as Camden Woods Apartments), located in the Westshore district of Tampa, FL. The loan was originated by Donny Rosenberg of…

BioXcel’s BXCL101, Receives Orphan Drug Designation from the U.S. FDA for the Treatment of Patients with Neurofibromatosis Type 2 (NF2)

BRANFORD, Conn., Sept. 13, 2016 (GLOBE NEWSWIRE) -- BioXcel, a privately held biopharmaceutical company based in Connecticut, today announced that the U. S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BXCL101 for the treatment of Neurofibromatosis Type 2 (NF2), an orphan disease with significant unmet medical need.  BXCL101 is the first…

Pentaho Announces 2016 Excellence Award Winners

SAN FRANCISCO and ORLANDO, Fla., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Pentaho, a Hitachi Group Company, today announced the 2016 Excellence Award winners. The awards recognize the Pentaho customers responsible for the year’s most innovative and impactful implementations of Pentaho technology. Pentaho customers from around the world submitted their nominations in one of six categories,…

ENT and Allergy Associates, LLP(R) Port Jefferson/East Patchogue, NY Practitioner Recognized for her Outstanding Contributions to the Field of Otolaryngology

TARRYTOWN, N.Y., Sept. 13, 2016 (GLOBE NEWSWIRE) -- The ear, nose and throat specialists and sub-specialists of ENT and Allergy Associates (ENTA)-the nation's preeminent otolaryngology practice-have long valued support offered to clinicians by the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS). Year after year, so many of the Practice's 180+ physicians attend…

Molecular Diagnostics Market To Reach $17.9 Billion By 2024: Grand View Research, Inc.

San Francisco, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Global molecular diagnostics market is expected to reach over USD 17.9 billion by 2024, based on a new report by Grand View Research, Inc. Increasing prevalence of infectious diseases including human papillomavirus and influenza is expected to be the primary driving force for the growth of the molecular…

TripAdvisor Applauds the United States Congress for Supporting the Consumer Review Fairness Act

NEEDHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- TripAdvisor®, a chief industry proponent for consumers’ rights, applauds the U.S. Senate and House of Representatives for seeking to protect travelers through their passage of the Consumer Review Fairness Act. If signed into law by the President after being reconciled with the version of the bill that…

SigmaTron International, Inc. Reports First Quarter Financial Results for Fiscal 2017

ELK GROVE VILLAGE, Ill., Sept. 12, 2016 (GLOBE NEWSWIRE) -- SigmaTron International, Inc. (NASDAQ:SGMA), an electronic manufacturing services company, today reported revenues and earnings for the fiscal quarter ended July 31, 2016. Revenues decreased to $58.9 million in the first quarter of fiscal 2017 from $64.2 million for the same quarter in the prior year. …
Huntington Ingalls Industries Continues to Make Strides on Aircraft Carrier John F. Kennedy (CVN 79)

Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant

MADISON, Wis., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an oncology-focused biotechnology company, today announces that its lead therapeutic compound, CLR 131, currently in a Phase 1 clinical trial for multiple myeloma and preparing for a Phase 2 study in multiple myeloma and other hematologic malignancies, will be evaluated by…

Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development

NEWTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Humphrey A.R. Gardner MD, FCAP, as Senior Vice President, Clinical Development. Dr. Gardner will be responsible for clinical development planning and strategy, including building and leading clinical teams to achieve the Company’s long-term strategic…

Takeda and MacroGenics Announce the Conclusion of their MGD010 License and Option Agreement

Rockville, MD, Sept. 12, 2016 (GLOBE NEWSWIRE) -- and Osaka, Japan, Sept. 12, 2016 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced the…

Athersys Announces Acceptance by PMDA of Clinical Trial Notification in Japan for Treatment of Ischemic Stroke With MultiStem®

CLEVELAND, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the successful completion of Japan’s Pharmaceutical and Medical Devices Agency (PMDA) review of the Clinical Trial Notification (CTN), allowing the commencement by HEALIOS K.K. (Healios) of a confirmatory clinical trial evaluating the safety and efficacy of administration of MultiStem®, Athersys’ novel cell therapy…

Neurostimulation Devices Market Worth $9.8 Billion By 2024: Grand View Research, Inc.

San Francisco, Sept. 12, 2016 (GLOBE NEWSWIRE) -- The neurostimulation devices market is expected to reach USD 9.8 billion by 2024, according to a new report by Grand View Research, Inc. The neurostimulation devices market is anticipated to witness a significant growth during the study period from 2016 to 2024. This growth is majorly attributed to…

Amarin’s REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee

BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced that, as expected, the independent data monitoring committee (DMC) has completed its review of the first pre-specified interim efficacy analysis for the REDUCE-IT cardiovascular outcomes study and has recommended that the trial continue as planned without modification. The 8,175-patient…

OHA Investment Corporation Announces New Credit Facility

NEW YORK, Sept. 09, 2016 (GLOBE NEWSWIRE) -- OHA Investment Corporation (NASDAQ:OHAI) (the “Company”) today announced that it has closed a new $56.5 million secured term loan credit facility (“Credit Facility”) with MidCap Financial, which replaces the Company’s existing investment facility. Initial proceeds of $40.5 million from this Credit Facility were used to pay off…
1 2 3 69Next →